- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Prevention science.
Displaying page 1 of 2.
EudraCT Number: 2007-006602-24 | Sponsor Protocol Number: PNC-2007 | Start Date*: 2008-03-31 |
Sponsor Name:Department of Pediatrics, Medical and Health Science Center, University of Debrecen | ||
Full Title: Relative adrenal insufficiency in children with pneumonia and sepsis. Efficacy of i.v. prednisolon for prevention of complication of pneumonia. A prospective, parallel-group, randomised trial. | ||
Medical condition: Severe complications of bacterial pneumonia i.e. abscess formation, empyema and sepsis in children. Supposed concomittant andrenal insuficiency is also planned to investigate. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002730-16 | Sponsor Protocol Number: GLS27-005 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:GeneOne Life Science Inc. | |||||||||||||
Full Title: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis caused by SARS-CoV-2 Infection | |||||||||||||
Medical condition: Patients with SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001417-26 | Sponsor Protocol Number: STW/K/01707 | Start Date*: 2009-01-22 |
Sponsor Name:Steigerwald Arzneimittelwerk GmbH | ||
Full Title: Double blind, randomized, placebo-controlled, mulitcentric clinical trial to evaluate the relapse prevention of a hypericum extract in outdoor patients with moderate depressive episodes (major depr... | ||
Medical condition: Moderate depressive episodes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003129-23 | Sponsor Protocol Number: 04/MR/111 | Start Date*: 2006-04-18 |
Sponsor Name:Belfast Health and Social Care Trust, Musgrave Park Hospital | ||
Full Title: Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases | ||
Medical condition: Children and adolescents with Juvenile Idiopathic arthritis (JIA), Juvenile dermatomyositis (JDMS) Juvenile systemic lupus erythematosis (JSLE) Vasculitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002404-41 | Sponsor Protocol Number: MOSES | Start Date*: 2022-08-26 |
Sponsor Name:PD Dr. med. Mira Katan | ||
Full Title: Midregional proatrial natriuretic peptide to guide secondary stroke prevention: The MOSES-study | ||
Medical condition: Patients with ischemic stroke and elevated midregional proatrial natriuretic peptide (MRproANP) levels without known atrial fibrillation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000610-39 | Sponsor Protocol Number: ITI101711 | Start Date*: 2005-12-15 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | ||
Full Title: A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery. | ||
Medical condition: Venous Thromboembolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) LT (Completed) LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003386-18 | Sponsor Protocol Number: CandMigIII | Start Date*: 2019-12-18 | |||||||||||
Sponsor Name:Department of Neurology and Clinical Neurophysiology, St Olavs Hospital, Trondheim University hospital | |||||||||||||
Full Title: CandMig III study Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg) | |||||||||||||
Medical condition: Episodic migraine with and without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000781-37 | Sponsor Protocol Number: NKV102549 | Start Date*: 2006-07-24 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon... | ||
Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002124-24 | Sponsor Protocol Number: ROPROP | Start Date*: 2017-12-22 |
Sponsor Name:Universität Zürich | ||
Full Title: Oral Propranolol for prevention of threshold retinopathy of prematurity | ||
Medical condition: Retinopathy of prematurity | ||
Disease: | ||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: View results |
EudraCT Number: 2017-002855-27 | Sponsor Protocol Number: IN-CA-311-3963/CTN299 | Start Date*: 2018-01-22 | |||||||||||
Sponsor Name:UNIVERSITY HEALTH NETWORK | |||||||||||||
Full Title: BonE health in ageING Women: Improvement or prevention of changes in Bone Mineral Density by Switching Antiretroviral Agents. Is there an optimal time to intervene? | |||||||||||||
Medical condition: HIV infection and menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002068-30 | Sponsor Protocol Number: ITI-007-304 | Start Date*: 2021-12-16 | |||||||||||
Sponsor Name:Intra-Cellular Therapies, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel- group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002203-15 | Sponsor Protocol Number: PregMet2 | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:NTNU, Norwegian University of Science and Technology | |||||||||||||
Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study | |||||||||||||
Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002176-41 | Sponsor Protocol Number: 17HH4268 | Start Date*: 2019-09-03 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Imperial College of Science Technology and Medicine | ||||||||||||||||||||||||||||||||||||||
Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001974-27 | Sponsor Protocol Number: STOPFLU | Start Date*: 2019-10-15 | |||||||||||||||||||||
Sponsor Name:Centre Hospitalier Universitaire Vaudois (CHUV) | |||||||||||||||||||||||
Full Title: Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial [Swiss Trial in solid Organ transplantation on Prevention of inFLUenza] | |||||||||||||||||||||||
Medical condition: Influenza in solid organ transplant patients | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003244-27 | Sponsor Protocol Number: PANORAMIC-Norway | Start Date*: 2023-04-11 | ||||||||||||||||
Sponsor Name:Helse Bergen HF | ||||||||||||||||||
Full Title: PAxlovid loNg cOvid-19 pRevention triAl with recruitMent In the Community in Norwayy | ||||||||||||||||||
Medical condition: COVID-19 SARS-CoV-2 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003231-19 | Sponsor Protocol Number: ViRap | Start Date*: Information not available in EudraCT |
Sponsor Name:The Children's Memorial Health Institute | ||
Full Title: Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T... | ||
Medical condition: Tuberous Sclerosis Complex Epilepsy Tumors associated with Tuberous Sclerosis Complex | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000570-35 | Sponsor Protocol Number: 01-2015 | Start Date*: 2016-02-10 | |||||||||||||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||||||||||||
Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration. | |||||||||||||||||||||||
Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002282-19 | Sponsor Protocol Number: MENAC-2017-03 | Start Date*: 2016-05-17 |
Sponsor Name:Norwegian University of Science and technology | ||
Full Title: A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in a... | ||
Medical condition: cachexia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002343-14 | Sponsor Protocol Number: FMD-TRI-2017-01 | Start Date*: 2018-01-27 | |||||||||||
Sponsor Name:Ferrer Internacional, S.A. | |||||||||||||
Full Title: A multicentre, randomised, open-label, parallel-group trial to study the safety and efficacy of a new therapeutic strategy (Trinomia®*) versus usual care on LDLc and blood pressure levels in patien... | |||||||||||||
Medical condition: Patients with atherothrombotic cardiovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) ES (Ongoing) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013056-71 | Sponsor Protocol Number: TC-2402-038-SP | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:Takeda Pharma A/S | |||||||||||||
Full Title: TachoSil versus current practice in dura sealing techniques for the prevention of post-operative cerebrospinal fluid (CSF) leaks in patients undergoing skull base surgery: An open label, randomised... | |||||||||||||
Medical condition: Skull base surgery for the prevention of postoperative cerebrospinal fluid (CSF) leaks | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) FI (Prematurely Ended) SE (Completed) DE (Completed) NL (Completed) GR (Completed) ES (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
